Scott Adams

Dr. Scott Adams

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Journal of Communication Disorders
Verified
Journal Article
Closed access
JCJenna P. Clark
Jenna P. Clark
SAScott Adams
Scott Adams
ADAllyson D. Dykstra
Allyson D. Dykstra
SMShane Moodie
Shane Moodie
Mandar JogMandar Jog
Mandar Jog


6 December 2018 in Movement Disorders Clinical Practice
Verified
Journal Article
Closed access
PDF file
HIHannah Im
Hannah Im
SAScott Adams
Scott Adams
AAAnita Abeyesekera
Anita Abeyesekera
MPMarcus Pieterman
Marcus Pieterman
GGGreydon Gilmore
Greydon Gilmore
MJMandar Jog
Mandar Jog

10 April 2024 in Progress in Neurobiology
Verified
Journal Article
Open access
KSKjersti Eline Stige
Kjersti Eline Stige
SKSimon Ulvenes Kverneng
Simon Ulvenes Kverneng
SSSoumya Sharma
Soumya Sharma
GSGeir Olve Skeie
Geir Olve Skeie
ESErika Sheard
Erika Sheard
CTCharalampos Tzoulis
Charalampos Tzoulis
The STRAT-PARK initiative aims to provide a platform for stratifying Parkinson's disease (PD) into biological subtypes, using a bottom-up, multidisciplinary biomarker-based and data-driven approach. PD is a heterogeneous entity, exhibiting high interindividual clinicopathological variability. This diversity suggests that PD may encompass multiple distinct biological entities, each driven by different molecular mechanisms. Molecular stratification and identification of disease subtypes is therefore a key priority for understanding and treating PD. STRAT-PARK is a multi-center longitudinal cohort aiming to recruit a total of 2000 individuals with PD and neurologically healthy controls from Norway and Canada, for the purpose of identifying molecular disease subtypes. Clinical assessment is performed annually, whereas biosampling, imaging, and digital and neurophysiological phenotyping occur every second year. The unique feature of STRAT-PARK is the diversity of collected biological material, including muscle biopsies and platelets, tissues particularly useful for mitochondrial biomarker research. Recruitment rate is ~150 participants per year. By March 2023, 252 participants were included, comprising 204 cases and 48 controls. STRAT-PARK is a powerful stratification initiative anticipated to become a global research resource, contributing to personalized care in PD.

4 June 2021 in Journal of Speech, Language, and Hearing Research
Verified
Journal Article
Closed access
TKThea Knowles
Thea Knowles
SAScott Adams
Scott Adams
Mandar JogMandar Jog
Mandar Jog
Purpose: The aim of this study was to quantify changes in speech intelligibility in two cohorts of people with Parkinson's disease (PD; those with and without deep brain stimulation [DBS]) across a broad range of self-selected speech rate alterations in (a) read sentences and (b) extemporaneous speech (monologues).Method: Four speaker groups participated in this study: younger and older controls, people with PD undergoing standard pharmaceutical treatment, and people with PD and DBS. Naïve listeners rated the intelligibility of read sentences and extemporaneous monologues, spoken by participants at seven self-selected speech rates from very slow to very fast. Intelligibility was modeled as a function of group, speech rate condition, and speech task.Results: Overall, compared to habitual speech rate, slower speech rate conditions were not associated with changes in speech intelligibility, whereas faster-than-habitual conditions were associated in declines in intelligibility. Results were mediated by group and task effects, such that talkers with PD and DBS were more likely to see intelligibility benefits at slower self-selected speech rates and less likely to see detriments at faster rates, and these differences were amplified in monologues compared to sentences.Conclusion: Findings suggest differences in the ways in which slower and faster speech rate adjustments impact speech intelligibility in people with PD with and without DBS, with the latter demonstrating greater magnitudes of change.